Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy - Archive ouverte HAL Access content directly
Journal Articles Clinical Medicine Insights: Oncology Year : 2016

Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy

, , (1) , , , , , , , , , , , , ,
1
Clotilde Verlut
  • Function : Author
Guillaume Mouillet
  • Function : Author
Eloi Magnin
Joëlle Buffet-Miny
  • Function : Author
Gabriel Viennet
  • Function : Author
Françoise Cattin
  • Function : Author
Nora Clelia Billon-Grand
  • Function : Author
Emilie Bonnet
  • Function : Author
Stéphanie Servagi-Vernat
Joël Godard
  • Function : Author
Romain Billon-Grand
  • Function : Author
Antoine Petit
  • Function : Author
Thierry Moulin
Laurent Cals
  • Function : Author
Xavier Pivot
  • Function : Author
Elsa Curtit
  • Function : Author

Abstract

Introduction Temozolomide and concomitant radiotherapy followed by temozolomide has been used as a standard therapy for the treatment of newly diagnosed glioblastoma multiform since 2005. A search for prognostic factors was conducted in patients with glioblastoma routinely treated by this strategy in our institution. Methods This retrospective study included all patients with histologically proven glioblastoma diagnosed between June 1, 2005, and January 1, 2012, in the Franche-Comté region and treated by radiotherapy (daily fractions of 2 Gy for a total of 60 Gy) combined with temozolomide at a dose of 75 mg/m 2 per day, followed by six cycles of maintenance temozolomide (150–200 mg/m 2 , five consecutive days per month). The primary aim was to identify prognostic factors associated with overall survival (OS) in this cohort of patients. Results One hundred three patients were included in this study. The median age was 64 years. The median OS was 13.7 months (95% confidence interval, 12.5–15.9 months). In multivariate analysis, age over 65 years (hazard ratio [HR] = 1.88; P = 0.01), Medical Research Council (MRC) scale 3–4 (HR = 1.62; P = 0.038), and occurrence of postoperative complications (HR = 2.15; P = 0.028) were associated with unfavorable OS. Conclusions This study identified three prognostic factors in patients with glioblastoma eligible to the standard chemotherapy and radiotherapy treatment. Age over 65 years, MRC scale 3–4, and occurrence of postoperative complications were associated with unfavorable OS. A simple clinical evaluation including these three factors enables to estimate the patient prognosis. MRC neurological scale could be a useful, quick, and simple measure to assess neurological status in glioblastoma patients.

Dates and versions

hal-03630204 , version 1 (04-04-2022)

Identifiers

Cite

Clotilde Verlut, Guillaume Mouillet, Eloi Magnin, Joëlle Buffet-Miny, Gabriel Viennet, et al.. Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy. Clinical Medicine Insights: Oncology, 2016, 10, pp.CMO.S38474. ⟨10.4137/CMO.S38474⟩. ⟨hal-03630204⟩

Collections

UNIV-FCOMTE
11 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More